FDA approval

migraine, nursing journal, healthcare, nursing

FDA approves new treatment for migraine

On October 11, 2019, the Food and Drug Administration (FDA) announced a new acute, short-term treatment for patients with migraine. (more…)

FDA Approves New Treatment for Scleroderma

In early September 2019, the Food and Drug Administration (FDA) approved a new orphan drug for individuals who face a decline in their pulmonary function due to a…

FDA launches mobile app on antiretrovirals

On Jan. 29, the FDA launched an interactive database that will offer a wealth of critical information about antiretrovirals eligible for purchase under the President’s Emergency Plan for…

First FDA approved treatment for thyroid eye disease

The U.S. Food and Drug Administration (FDA) recently approved Horizon Therapeutics Ireland DAC’s teprotumumab-trbw (Tepezza) as the first FDA-approved treatment for adults with thyroid eye disease (TED). (more…)

New treatment for acute hepatic porphyria

The U.S. Food and Drug Administration (FDA) recently granted approval to Alnylam Pharmaceuticals’ givosiran (Givlaari), a new treatment for adult patients with acute hepatic porphyria (AHP).    (more…)

New treatment for advanced epithelioid sarcoma

The U.S. Food and Drug Administration (FDA) recently approved Epizyme, Inc’s tazemetostat (TAZVERIK) for the treatment of adult and pediatric patients with metastatic or advanced epithelioid sarcoma (AES).…

New treatment for cystic fibrosis

The U.S. Food and Drug Administration has approved a new “breakthrough therapy” for cystic fibrosis (CF) in late October 2019. (more…)

New treatment for multiple myeloma

The U.S. Food and Drug Administration (FDA) recently approved Sanofi-Aventis’ Sarclisa (isatuximab-irfc) for the treatment of  adult patients with multiple myeloma. Isatuximab-irfc was previously designated its orphan drug…

New treatment for peanut allergy in children

The U.S. Food and Drug Administration (FDA) recently approved Aimmune Therapeutics’ Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] for children suffering from peanut allergy. (more…)

Potential new treatment for atopic dermatitis

Eczema is a common ailment for many people, but a more severe type of eczema not as well-known, atopic dermatitis (AD), may have a new treatment option available.…

Potential new treatment for peanut allergies

Aimmune Therapeutics is set to present new data on its AR101 compound, Palforzia, a potential new treatment for peanut allergies, in early November 2019 at the American College…

New treatment for acute hepatic porphyria

The U.S. Food and Drug Administration (FDA) recently granted approval to Alnylam Pharmaceuticals’ givosiran (Givlaari), a new treatment for adult patients with acute hepatic porphyria (AHP).    (more…)

New treatment for cystic fibrosis

The U.S. Food and Drug Administration has approved a new “breakthrough therapy” for cystic fibrosis (CF) in late October 2019. (more…)

New treatment for multiple myeloma

The U.S. Food and Drug Administration (FDA) recently approved Sanofi-Aventis’ Sarclisa (isatuximab-irfc) for the treatment of  adult patients with multiple myeloma. Isatuximab-irfc was previously…

New treatment for peanut allergy in children

The U.S. Food and Drug Administration (FDA) recently approved Aimmune Therapeutics’ Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] for children suffering from peanut allergy. (more…)

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Survey

Test Your Knowledge

Which of the following best describes Wegovy’s FDA-approved use?

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.